Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
The treatment of various central nervous system (CNS) diseases has been challenging, despite the rapid development of several novel treatment approaches. The blood–brain barrier (BBB) is one of the major issues in the treatment of CNS diseases, having major role in the protection of the brain but simultaneously constituting the main limiting hurdle for drugs targeting the brain. Nasal drug delivery has gained significant interest for brain targeting over the past decades, wherein the drug is directly delivered to the brain by the trigeminal and olfactory pathway. Various novel and promising formulation approaches have been explored for drug targeting to the brain by nasal administration. Nanoemulsions have the potential to avoid problems, including low solubility, poor bioavailability, slow onset of action, and enzymatic degradation. The present review highlights research scenarios of nanoemulsions for nose-to-brain delivery for the management of CNS ailments classified on the basis of brain disorders and further identifies the areas that remain unexplored. The significance of the total dose delivered to the target region, biodistribution studies, and long-term toxicity studies have been identified as the key areas of future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ahmad, N., Ahmad, R., Alam, M. A., Ahmad, F. J., & Amir, M. (2018) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2018.1489826 · Cited by 46
RetractedThe blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
Migraine prevalence, disease burden, and the need for preventive therapy
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007) · Neurology · doi:10.1212/01.wnl.0000252808.97649.21 · Cited by 2,337
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Transport of drugs from the nasal cavity to the central nervous system
Illum, L. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00087-7 · Cited by 907 · cited 2×
“and thus, it can provide systemic drug absorption and, subsequently, indirect drug delivery to the brain after intranasal administration [11,12].”
BackgroundNanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734
Mechanism of intranasal drug delivery directly to the brain
Crowe, T. P., Greenlee, M. H. W., Kanthasamy, A. G., & Hsu, W. H. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.12.025 · Cited by 721
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Nanoemulsion components screening and selection: A technical note
Azeem, A., Rizwan, M., Ahmad, F. J., Iqbal, Z., Khar, R. K., Aqil, M., & Talegaonkar, S. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-008-9178-x · Cited by 567
Pardeshi, C. V., & Belgamwar, V. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.790887 · Cited by 482 · cited 3×
“Drugs can cross olfactory epithelial cells by moving slowly through the tight interstitial space of cells by passive diffusion or across the cell membrane by endocytosis, or they can be transported by neurons [4,18].”
BackgroundIntranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435 · cited 1×
“In vivo studies in Swiss albino rats with technetium (99mTc)-labeled NEs evidenced rapid and higher drug transport into the brain after the intranasal administration of the mucoadhesive NEs in comparison to the plain NE administered intranasally, intravenously, and as a solution [92].”
BackgroundSelf-citationInsights into Direct Nose to Brain Delivery: Current Status and Future Perspective
Mittal, D., Ali, A., Md, S., Baboota, S., Sahni, J. K., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838713 · Cited by 359 · cited 1×
“Olfactory neurons have an important role in drug targeting to the brain by intranasal administration [20].”
BackgroundRecent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.009 · Cited by 357 · cited 4×
“this range can be readily delivered through this pathway [8].”
BackgroundInfluentialSood, S., Jain, K., & Gowthamarajan, K. (2014) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.09.030 · Cited by 289
Nanoemulsions for “Nose-to-Brain” Drug Delivery
Bonferoni, M. C., Rossi, S., Sandri, G., Ferrari, F., Gavini, E., Rassu, G., & Giunchedi, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11020084 · Cited by 269
Engineering of nanoemulsions for drug delivery
Sarker, D. (2005) · Current Drug Delivery · doi:10.2174/156720105774370267 · Cited by 268
Neurotherapeutic applications of nanoparticles in Alzheimer’s disease
Sahni, J. K., Doggui, S., Ali, J., Baboota, S., Dao, L., & Ramassamy, C. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.11.033 · Cited by 219 · cited 1×
“Resveratrol is known for its clinical efficacy for reducing the production of amyloid peptides, in addition to the reduction of cognitive defects and its cytoprotective actions [73].”
BackgroundNanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting
Mahajan, H. S., Mahajan, M. S., Nerkar, P. P., & Agrawal, A. (2014) · Drug Delivery · doi:10.3109/10717544.2013.838014 · Cited by 212
Nasr, M. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1092619 · Cited by 208 · cited 1×
“Nasr (2016) co-encapsulated two polyphenols, curcumin and resveratrol (1:1 weight ratio), in mucoadhesive NEs made of hyaluronic acid for nose-to-brain targeting (Table 1).”
BackgroundEvidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles
Ahmad, E., Feng, Y., Qi, J., Fan, W., Ma, Y., He, H., Xia, F., Dong, X., Zhao, W., Lu, Y., et al. (2017) · Nanoscale · doi:10.1039/c6nr07581a · Cited by 194
Pangeni, R., Sharma, S., Mustafa, G., Ali, J., & Baboota, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/48/485102 · Cited by 192 · cited 2×
“The intranasal administration of an antioxidant vitamin E loaded with naringenin for the direct brain delivery for PD therapeutics was explored [70].”
BackgroundMucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting
Kumar, M., Misra, A., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · Journal of Drug Targeting · doi:10.1080/10611860802476504 · Cited by 179
Self-citationColombo, M., Figueiró, F., de Fraga Dias, A., Teixeira, H. F., Battastini, A. M. O., & Koester, L. S. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.03.055 · Cited by 157
Yadav, S., Gandham, S. K., Panicucci, R., & Amiji, M. M. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.12.374 · Cited by 125
Brain targeting efficiency of antimigrain drug loaded mucoadhesive intranasal nanoemulsion
Abdou, E. M., Kandil, S. M., & Miniawy, H. M. F. E. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.07.030 · Cited by 124
Kumar, S., Ali, J., & Baboota, S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/43/435101 · Cited by 115
Pathak, R., Prasad Dash, R., Misra, M., & Nivsarkar, M. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.02.002 · Cited by 113
Ahmad, N., Ahmad, R., Alam, M. A., Samim, M., Iqbal, Z., & Ahmad, F. J. (2016) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2016.03.019 · Cited by 110
Abbott, A. (2010) · Nature · doi:10.1038/466s6a · Cited by 109 · cited 1×
“Levodopa is a metabolic precursor of dopamine and is capable of traversing the BBB, where it gets converted into dopamine [68].”
BackgroundQuetiapine Nanoemulsion for Intranasal Drug Delivery: Evaluation of Brain-Targeting Efficiency
Boche, M., & Pokharkar, V. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-016-0552-9 · Cited by 109 · cited 1×
“The oral therapy of quetiapine shows low bioavailability (5–15%) due to poor water solubility and an extensive first-pass effect [58].”
BackgroundQuintana, D. S., Guastella, A. J., Westlye, L. T., & Andreassen, O. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.166 · Cited by 107
Infections of the nervous system
Parikh, V., Tucci, V., & Galwankar, S. (2012) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.97273 · Cited by 106
Pandey, Y. R., Kumar, S., Gupta, B. K., Ali, J., & Baboota, S. (2016) · Nanotechnology · doi:10.1088/0957-4484/27/2/025102 · Cited by 96
Yadav, S., Gattacceca, F., Panicucci, R., & Amiji, M. M. (2015) · Molecular Pharmaceutics · doi:10.1021/mp5008376 · Cited by 76 · cited 1×
“Furthermore, the intranasal NE reduced the nontarget organ exposure [55].”
BackgroundHaider, M. F., Khan, S., Gaba, B., Alam, T., Baboota, S., Ali, J., & Ali, A. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.01.123 · Cited by 68
H. Parikh, R., & J. Patel, R. (2016) · Current Drug Delivery · doi:10.2174/1567201813666151202195729 · Cited by 56
Bahadur, S., & Pathak, K. (2012) · Current Drug Delivery · doi:10.2174/156720112803529792 · Cited by 46 · cited 2×
“The optimized mucoadhesive NE was devoid of nasal ciliotoxicity in sheep nasal mucosa, concluding the development of the buffered mucoadhesive NE of ziprasidone hydrochloride, which can be safely administered by intranasal route [57].”
BackgroundMethodSelf-citationColombo, M., Melchiades, G. D. L., Figueiró, F., Battastini, A. M. O., Teixeira, H. F., & Koester, L. S. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.046 · Cited by 32
Cited by
Jeong, S.-H., Jang, J.-H., & Lee, Y.-B. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-022-00589-5 · Cited by 256
Khatri, D. K., Preeti, K., Tonape, S., Bhattacharjee, S., Patel, M., Shah, S., Singh, P. K., Srivastava, S., Gugulothu, D., Vora, L., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x20666220507022701 · Cited by 75
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59
“Transport through the trigeminal route can also oc ur intracellularly or extracellularly, as occurs with olfactory neurons [38].”
BackgroundTanaka, M., Araujo, A. C., Valenti, V. E., Guiguer, E. L., Catharin, V. C. S., Gualhardi, C. M., de Souza Bastos Mazuqueli Pereira, E., de Alvares Goulart, R., de Argolo Haber, R. S., de Carvalho, A. C. A., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052370 · Cited by 13
Metadata
- Authors
- Bahadur, S., Pardhi, D. M., Rautio, J., Rosenholm, J. M., & Pathak, K.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2020-12-18
- Volume
- 12
- Issue
- 12
- Pages
- 1230
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W3111965812
- Cited by
- 170
- References
- 39
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.